Zur Kurzanzeige

dc.contributor.authorFernández-González, Juan Francisco
dc.contributor.authorGarcía Pedraza, José Ángel 
dc.contributor.authorTerol-Úbeda, Anaïs Clara
dc.contributor.authorMartín Calvo, María Luisa 
dc.contributor.authorMorán Benito, Asunción 
dc.contributor.authorGarcía Domingo, Mónica 
dc.date.accessioned2025-02-14T13:13:06Z
dc.date.available2025-02-14T13:13:06Z
dc.date.issued2024-07
dc.identifier.citationFernández-González, J. F., García-Pedraza, J. Á., Terol-Úbeda, A. C., Martín, M. L., Morán, A., & García-Domingo, M. (2024). Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes. Biomedicine & Pharmacotherapy, 176, 116814.https://doi.org/10.1016/j.biopha.2024.116814es_ES
dc.identifier.issn0753-3322
dc.identifier.urihttp://hdl.handle.net/10366/163737
dc.description.abstract[EN]Diabetes and derived complications, especially diabetic nephropathy and neuropathy annually cause great morbimortality worldwide. 5-hydroxytryptamine (5-HT) acts as a modulator of renal sympathetic input and vascular tone. In this line, 5-HT2 receptor blockade has been linked with reduced incidence and progression of diabetic microvascular alterations. In this work, we aimed to determine, in diabetic rats, whether 5-HT2 blockade ameliorates renal function and to characterize the serotonergic modulatory action on renal sympathetic neurotransmission. Diabetes was induced in male Wistar rats by alloxan administration (150 mg/kg, s.c.), and sarpogrelate (30 mg/kg·day, p.o.; 5-HT2 antagonist) was administered for 14 days (DM-S). Normoglycemic and diabetic (DM) animals were maintained as aged-matched controls. At 28th day, DM-S animals were anesthetized and prepared for the in situ autoperfusion of the kidney. Renal vasoconstrictor responses were induced electrically or by i.a. noradrenaline (NA) administration. The role of 5-HT and selective 5-HT agonist/antagonist were studied on these renal vasopressor responses. Sarpogrelate treatment decreased renal sympathetic-induced vasopressor responses, reduced renal hypertrophy and kidney damage markers increased in DM. Intraarterial 5-HT inhibited the sympathetic-induced renal vasoconstrictions, effect reproduced by 5-CT, AS-19, L-694,247 and LY 344864 (5-HT1/5/7, 5-HT7, 5-HT1D and 5-HT1F receptor agonists, respectively). Blocking 5-HT1D/1F/7 receptors completely abolished the 5-CT sympatho-inhibition. NA vasoconstrictions were not altered by any of the 5-HT agonists tested. Thus, in experimental diabetes, chronic sarpogrelate treatment reduces renal damage markers, kidney hypertrophy and renal sympathetic hyperactivity and modifies serotonergic modulation of renal sympathetic neurotransmission, causing a sympatho-inhibition by prejunctional 5-HT1D/1F and 5-HT7 activation.es_ES
dc.format.mimetypeapplication/pdf
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/*
dc.subject5-HT modulationes_ES
dc.subjectdiabeteses_ES
dc.subjectnephropathyes_ES
dc.subjectsarpogrelatees_ES
dc.subjectsympathetic neurotransmissiones_ES
dc.subjectsympatholytic effectes_ES
dc.subject.meshSerotonin *
dc.subject.meshSerotonin 5-HT2 Receptor Antagonists *
dc.subject.meshDiabetes Mellitus *
dc.subject.meshRats *
dc.subject.meshAnimals *
dc.subject.meshVasoconstriction *
dc.subject.meshKidney *
dc.subject.meshDiabetic Nephropathies *
dc.subject.meshSympathetic Nervous System *
dc.titleChronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1016/j.biopha.2024.116814es_ES
dc.subject.unesco3209 Farmacologíaes_ES
dc.identifier.doi10.1016/j.biopha.2024.116814
dc.relation.projectIDUniversity of Salamanca (project number 18.K233 / 463AC01)es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid38820974
dc.identifier.essn1950-6007
dc.journal.titleBiomedicine and Pharmacotherapyes_ES
dc.volume.number176es_ES
dc.page.initial116814es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsvasoconstricción *
dc.subject.decsantagonistas de receptores de serotonina 5-HT2 *
dc.subject.decsriñón *
dc.subject.decsanimales *
dc.subject.decsserotonina *
dc.subject.decsratas *
dc.subject.decsnefropatías diabéticas *
dc.subject.decsdiabetes mellitus *
dc.subject.decssistema nervioso simpático *


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NoDerivatives 4.0 Internacional